Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | APLNR | P35414 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393197 | 1.00 | CA1 (0.52) | CA1CA2APLNRCA7CA12 | |
| SCHEMBL1648801 | 1.00 | CA1 (0.52) | CA1CA2APLNRCA7CA12 | |
| SCHEMBL19479300 | 1.00 | CA1 (0.52) | CA1CA2APLNRCA7CA12 | |
| SCHEMBL21943788 | 1.00 | CA1 (0.52) | CA1CA2APLNRCA7CA12 | |
| SCHEMBL19066054 | 1.00 | CA1 (0.52) | CA1CA2APLNRCA7CA12 | |
| SCHEMBL14462832 | 1.00 | CA1 (0.52) | CA1CA2APLNRCA7CA12 | |
| Hydrochloric Acid SCHEMBL21598754 | 0.97 | CA1 (0.50) | CA1CA2APLNRCA7CA12 | |
| SCHEMBL244348 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29086421 | 0.94 | APLNR (0.52) | CA1CA2APLNRCA7CA12 | |
| SCHEMBL636980 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-114026199-B | Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| US-11802208-B2 | Stilbene-based compound or salt thereof, and polarizing film, polarizing plate, and display device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-116034036-A | Thermosensitive recording material | 日本化药株式会社 | 2023-04-28 | — | — | CN | disclosed |
| US-20230082516-A1 | 15-PGDH INHIBITOR | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-16 | — | — | US | disclosed |
| US-20230019461-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-110945083-B | Styrene compound or salt thereof, polarizing film, polarizing plate and display device | 日本化药株式会社 | 2022-07-01 | — | — | CN | disclosed |
| EP-3998502-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | Nippon Kayaku Kabushiki Kaisha (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-3922247-A1 | 15-PGDH INHIBITOR | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-15 | — | — | EP | disclosed |
| EP-3917911-A1 | 15-PGDH INHIBITORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO. INC (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1847527-A1 | NOVEL BENZAMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-5281572-A | Heating dye containing transfer sheet in imagewise fashion thereby transferring the bichromophoric methine dye from transfer sheet to sheet of plastic coated receiving sheet | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-25 | — | — | US | disclosed |
| EP-0441282-B1 | Bichromophore methine and azamethine dyestuffs and a process for their transfer | BASF AG (DE) | 1993-12-15 | — | — | EP | disclosed |
| US-5214140-A | Thermal printing | BASF AKTIENGESELLSCHAFT (DE) | 1993-05-25 | — | — | US | disclosed |
| US-5132438-A | Thermal transfer | BASF AKTIENGESELLSCHAFT (DE) | 1992-07-21 | — | — | US | disclosed |
| EP-0441282-A1 | Bichromophore methine and azamethine dyestuffs and a process for their transfer | BASF Aktiengesellschaft (DE) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230082516-A1 | 15-PGDH INHIBITOR | UGDH, HPGD, GCDH | CA1 3243/4885CA2 1328/4885APLNR 3207/4885 |
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | CA1 2306/4885CA2 1771/4885APLNR 3129/4885 |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | CA1 4255/4885CA2 3239/4885APLNR 3214/4885 |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | CA1 2306/4885CA2 1771/4885APLNR 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.